Gilenya’s Optimal Dose for RRMS Confirmed in Review of Clinical Trials

Gilenya’s Optimal Dose for RRMS Confirmed in Review of Clinical Trials

296339

Gilenya’s Optimal Dose for RRMS Confirmed in Review of Clinical Trials

Gilenya (fingolimod) at its approved 0.5 mg daily dose continues to be the optimal dose for people with relapsing-remitting MS (RRMS), a systematic review of 11 clinical trials confirmed. A 0.25 mg/day dose, however, also showed improvement over placebo in MRI outcomes and patient satisfaction, the researchers noted, and further studies are warranted to better evaluate Gilenya at this lower daily dose. The review study, “Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and…

You must be logged in to read/download the full post.